S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
S&P 500   4,284.40 (+1.50%)
DOW   33,769.37 (+2.14%)
QQQ   354.44 (+0.69%)
AAPL   180.46 (+0.21%)
MSFT   335.26 (+0.81%)
META   272.64 (+0.01%)
GOOGL   124.78 (+0.86%)
AMZN   124.64 (+1.52%)
TSLA   215.25 (+3.72%)
NVDA   392.35 (-1.35%)
NIO   7.62 (+1.06%)
BABA   84.79 (+2.16%)
AMD   118.16 (-1.10%)
T   15.13 (-4.30%)
F   12.40 (+2.39%)
MU   69.17 (+0.12%)
CGC   0.83 (-1.03%)
GE   106.20 (+1.46%)
DIS   91.04 (+2.77%)
AMC   4.54 (-0.22%)
PFE   38.49 (+1.24%)
PYPL   63.92 (+1.38%)
NFLX   402.17 (-0.24%)
NASDAQ:BCRX

BioCryst Pharmaceuticals (BCRX) News Today

$8.35
-0.04 (-0.48%)
(As of 02:27 PM ET)
Compare
Today's Range
$8.30
▼
$8.49
50-Day Range
$7.37
▼
$8.77
52-Week Range
$7.20
▼
$15.43
Volume
895,936 shs
Average Volume
2.93 million shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.



BCRX Media Mentions By Week

BCRX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BCRX
News Sentiment
▼
0.35

0.49
▲
Average
Medical
News Sentiment

BCRX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BCRX Articles
This Week
▼
3

3
▲
BCRX Articles
Average Week

SourceHeadline
finance.yahoo.com logoBioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 European Academy of Allergy and Clinical Immunology Congress
finance.yahoo.com - May 31 at 9:29 AM
seekingalpha.com logoBioCryst Pharmaceuticals: An Updated View
seekingalpha.com - May 31 at 3:44 AM
marketbeat.com logoGW&K Investment Management LLC Has $19.83 Million Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - May 26 at 9:14 AM
marketbeat.com logoRussell Investments Group Ltd. Buys 23,818 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - May 23 at 4:43 AM
marketbeat.com logoTekla Capital Management LLC Acquires 323,135 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - May 22 at 11:10 AM
markets.businessinsider.com logoBioCryst Pharma Receives Approval Of ORLADEYO From Public Health Institute Of Chile
markets.businessinsider.com - May 22 at 10:42 AM
finance.yahoo.com logoBioCryst Announces Approval of ORLADEYO® (berotralstat) by the Public Health Institute of Chile
finance.yahoo.com - May 22 at 10:42 AM
marketbeat.com logoVictory Capital Management Inc. Sells 986,833 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - May 21 at 5:52 AM
marketbeat.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Purchased by Artisan Partners Limited Partnership
marketbeat.com - May 19 at 9:37 AM
marketbeat.com logoCommonwealth Equity Services LLC Has $1.78 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - May 18 at 4:35 AM
MarketBeat logoBrokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.00
americanbankingnews.com - May 14 at 4:16 AM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded by StockNews.com to Hold
americanbankingnews.com - May 14 at 3:37 AM
MarketBeat logoReviewing BioCryst Pharmaceuticals (NASDAQ:BCRX) and ImmunityBio (NASDAQ:IBRX)
americanbankingnews.com - May 12 at 3:26 AM
marketbeat.com logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Lowered to Hold at StockNews.com
marketbeat.com - May 12 at 1:20 AM
finance.yahoo.com logoBioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) institutional shareholders had a great week as one-year returns increased after a 13% gain last week
finance.yahoo.com - May 9 at 12:56 PM
MarketBeat logoQ2 2023 Earnings Estimate for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Issued By HC Wainwright
americanbankingnews.com - May 9 at 2:40 AM
marketbeat.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts
marketbeat.com - May 9 at 1:40 AM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Upgraded to "Buy" at StockNews.com
americanbankingnews.com - May 8 at 5:00 AM
marketbeat.com logoQ2 2023 EPS Estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Reduced by Analyst
marketbeat.com - May 8 at 2:33 AM
marketbeat.com logoHC Wainwright Comments on BioCryst Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:BCRX)
marketbeat.com - May 5 at 8:43 AM
msn.com logoBioCryst gains 14% most since February after Q1 2023 results
msn.com - May 3 at 5:24 PM
finance.yahoo.com logoBioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
finance.yahoo.com - May 3 at 5:24 PM
msn.com logoBioCryst Clocks 37.8% Revenue Growth In Q1 On Solid New Patient Growth
msn.com - May 3 at 12:23 PM
seekingalpha.com logoBioCryst Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 3 at 8:58 AM
msn.com logoBioCryst Pharmaceuticals GAAP EPS of -$0.28 beats by $0.03, revenue of $68.78M misses by $2.66M
msn.com - May 3 at 7:23 AM
finance.yahoo.com logoBioCryst Reports First Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - May 3 at 7:23 AM
marketbeat.com logoState of New Jersey Common Pension Fund D Acquires 22,658 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - April 28 at 5:08 AM
finance.yahoo.com logoBioCryst Presents New Long-term Data Demonstrating Consistently High Attack-free Status Among Hereditary Angioedema Patients with ORLADEYO® (berotralstat)
finance.yahoo.com - April 27 at 7:56 AM
MarketBeat logoBioCryst Pharmaceuticals (BCRX) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 26 at 6:32 AM
MarketBeat logoBioCryst Pharmaceuticals (NASDAQ:BCRX) Receives "Buy" Rating from Needham & Company LLC
americanbankingnews.com - April 24 at 3:24 AM
MarketBeat logoEvercore ISI Trims BioCryst Pharmaceuticals (NASDAQ:BCRX) Target Price to $10.00
americanbankingnews.com - April 23 at 2:48 AM
bizjournals.com logoPharma with Bham presence takes $300M loan to pay down debt
bizjournals.com - April 21 at 5:09 AM
msn.com logoEvercore ISI Group Maintains Biocryst Pharmaceuticals (BCRX) Outperform Recommendation
msn.com - April 20 at 10:35 PM
msn.com logoNeedham Reiterates Biocryst Pharmaceuticals (BCRX) Buy Recommendation
msn.com - April 20 at 10:35 PM
bizjournals.com logoDurham pharma takes $300M loan to pay down debt
bizjournals.com - April 20 at 12:34 PM
finance.yahoo.com logoBioCryst to Report First Quarter 2023 Financial Results on May 3
finance.yahoo.com - April 19 at 10:55 AM
MarketBeat logoAnalysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $16.43
americanbankingnews.com - April 19 at 3:55 AM
markets.businessinsider.com logoWhy Is BioCryst Pharmaceuticals (BCRX) Stock Down 8% Today?
markets.businessinsider.com - April 18 at 1:00 PM
finance.yahoo.com logoBioCryst Refinances Existing Debt with $450 Million Financing Commitment from Pharmakon
finance.yahoo.com - April 18 at 7:59 AM
finance.yahoo.com logoLacklustre Performance Is Driving BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S
finance.yahoo.com - April 17 at 4:58 PM
seekingalpha.com logoBCRX BioCryst Pharmaceuticals, Inc.
seekingalpha.com - April 15 at 8:40 AM
seekingalpha.com logoThe Big Short: 5 Stocks At Risk With High Short Interest
seekingalpha.com - April 12 at 6:00 AM
bizjournals.com logoRobert Ingram, pillar of Triangle pharma industry, dies
bizjournals.com - March 30 at 8:09 AM
finance.yahoo.com logoBioCryst Celebrates Bob Ingram’s Contributions to the Company’s Success
finance.yahoo.com - March 29 at 8:55 PM
MarketBeat logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $16.13 Consensus Price Target from Brokerages
americanbankingnews.com - March 23 at 3:54 AM
marketbeat.com logoAssenagon Asset Management S.A. Trims Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - March 22 at 5:28 AM
marketbeat.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Average Recommendation of "Moderate Buy" from Analysts
marketbeat.com - March 20 at 2:15 AM
marketbeat.com logoNorth Star Investment Management Corp. Has $4.22 Million Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - March 19 at 9:43 AM
seekingalpha.com logoBioCryst's Commercialization Of Orladeyo: Risks Materializing, A Shorting Opportunity
seekingalpha.com - March 16 at 5:50 PM
marketbeat.com logoEngineers Gate Manager LP Buys New Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
marketbeat.com - March 9 at 6:42 AM
Get BioCryst Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BCRX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:BCRX) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -